Failure of critically ill patients to metabolise midazolam.
about
A prospective randomised pilot study of sedation regimens in a general ICU population: a reality-based medicine studyInstruments for monitoring intensive care unit sedationComparison of train-of-four and best clinical assessment during continuous paralysisBenzodiazepine withdrawal reaction in two children following discontinuation of sedation with midazolamThe immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients.Disturbed memory and amnesia related to intensive care.Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.The pharmacokinetics of midazolam following orthotopic liver transplantationExtra-hepatic metabolism of midazolam.Sedation assessment in critically ill adults.Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.Isoflurane compared with midazolam for sedation in the intensive care unitComparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.Regulation of drug metabolism and disposition during inflammation and infection.Clinical pharmacokinetic monitoring of midazolam in critically ill patients.Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers.Safety and efficacy of dexmedetomidine for long-term sedation in critically ill patients.Assisted ventilation. 3. General care of the ventilated patient in the intensive care unit.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Pain management in neurocritical care.Therapeutic progress--review XXXI. Therapeutic progress in intensive care sedation and analgesia. Part II--Drug selection.Pharmacokinetics and pharmacodynamics in the critically ill patient.The effects of hypoxia on drug-metabolizing enzymes.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Regulation of cytochromes P450 during inflammation and infection.Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a bayesian pharmacokinetic software (PKS) according to sparse sampling approach.Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.Midazolam for continuous sedation in Japanese patients in the critical care setting: phase II study.Midazolam for continuous sedation in Japanese critical care patients: phase II study.CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Co-sedation in the critically ill.Sedation and analgesia in the intensive care unit.Monitoring of sedation depth in intensive care unit by therapeutic drug monitoring? A prospective observation study of medical intensive care patients
P2860
Q24794122-8395A627-DCFF-464A-85E6-D3AFE3E9B337Q24801286-DB277D78-5ACA-4351-B461-BAEC76E6DE53Q28254873-A27C509F-6D7B-443F-B7C1-F6EDC67BA3B8Q28261267-967CA065-D61D-4FDF-BD1D-A630B018AD36Q31891589-065E0EDD-0572-402E-99F9-F2ECDC87B06EQ33928368-CB75513A-A26F-4D80-B9DD-FE5F18D479CAQ34227492-71C662A5-03F7-41BF-B879-7DC4D7C8EDB1Q34397693-4398B68C-EB18-4FE8-B24B-9E6C983D33FFQ34397699-52D18CE0-CDBD-434B-8E4A-3A365CF26291Q34495765-05B714E7-29D4-469C-AB84-4C898DED3C2BQ35579550-3B7A35CA-B69D-4224-B064-DC468BC61C0DQ35711931-6D9CA0CB-ECEE-4BE3-B0C3-6BF9B7E0BB20Q35825944-0880F580-4319-47E4-9662-275E205A608AQ36544874-20E60C6F-6675-4CFD-8BB5-E90246E3B0BFQ36742400-1C89C394-2A56-4551-B266-B2276D4B37FDQ37338726-A1E9329F-1567-4EAF-B45A-F1FB06F3E141Q37578512-11D27E04-6FE7-4BAE-AAFA-EB244B412B7AQ37832145-BA3BCC9B-ECB9-4AD8-A3A5-7EA1FCBA90F1Q38040844-4FEBB64A-F378-4127-A5F7-9C8047529DB2Q38124745-A7F43D50-9877-4083-947B-E3E8ADDBBE55Q39637643-951E50F7-7241-4E43-A703-6373E5E2964FQ40815584-2FC75342-3606-4571-A1AC-C8F4357CA3E3Q40923028-54A24E91-567A-479C-AC51-F5CF1197EC04Q41328717-E1D15B28-CFA2-420D-BD60-FDD735478E24Q41676809-89E10CAE-C63B-4EB1-98DC-75B359BA846EQ42166551-E62EDCBA-20FA-4708-99E3-FBCA5F23AFC1Q42993169-747A9614-64B4-4E10-86DB-AEDD132D7BD7Q43776248-C1F5696E-5075-43CB-9AF0-896189027AC7Q43776252-3BAB94A1-2F0F-4A23-9187-4FE4B7031C7FQ47951996-A555329E-D1A8-4F3E-82AB-80ED69C39F2EQ51589802-1ED55E12-19A5-4BAA-8C8B-1320CE0CC250Q51701092-ABC37EF8-0C50-49F2-A057-FA25AC3E8CFEQ57300343-30243A44-2BBC-4862-8349-F4920D2A8D07
P2860
Failure of critically ill patients to metabolise midazolam.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Failure of critically ill patients to metabolise midazolam.
@en
Failure of critically ill patients to metabolise midazolam.
@nl
type
label
Failure of critically ill patients to metabolise midazolam.
@en
Failure of critically ill patients to metabolise midazolam.
@nl
prefLabel
Failure of critically ill patients to metabolise midazolam.
@en
Failure of critically ill patients to metabolise midazolam.
@nl
P2093
P2860
P1433
P1476
Failure of critically ill patients to metabolise midazolam.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2044.1987.TB03086.X
P407
P577
1987-06-01T00:00:00Z